artificial intelligence in health care - stat€¦ · artificial intelligence the editorial content...

Post on 25-Jul-2020

1 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Artificial Intelligence

The editorial content in this presentation was written and produced by STAT with no participation from sponsors.

in Health Care

Investment in AI health startups

● mainly used in the back

● Clinical use is increasing

● Drug makers are using AI

● Financial costs:

● Privacy and ethical costs:

● Reputational costs:

● Imaging, imaging, imaging:

● A recent example:

● The benefit:

● pump the breaks

● AI might play a role in quality assurance and help surface research

● AI comes in many forms

● Two main tasks:

● A third use:

Machine learning:

Deep learning:

Neural network:

Natural language processing:

●schedule its operating rooms

● detect the onset of sepsis

target interventions to particular patients

● improving the R&D process

●examine the mechanisms of

disease

● helping with recruiting

processing and cleaning of data

● incorporate real-world evidence

● significant roadblocks to overcome

● The goal:

● The possibilities are enormous,

●unrealistic expectations

●skepticism and

anxiety

● slower adoption

●built in incentives to aggressively market

the use of AI

● sell their products

●work is cutting-edge to attract patients

●co-branding arrangements

● needs to be grounded in facts

● dispel hype, not peddle it.

The Gartner Hype Cycle

Source: www.gartner.com

POLL QUESTION

● two extremes

● replacing doctorscuring terminal disease

● the truth becomes much harder to suss out

● AI is designed to augment human capabilities

● doctors can focus on tasks that matter

● Human oversight will continue to be needed

● Progress is slow and incremental.

● Use in clinical practice remains largely experimental.

21st Century Cures Act

●products can be exempt from

regulation if users can “independently review

● has not clarified what it means

● left to determine on their own

● commercialization of IBM’s leading cancer product, Watson for Oncology,

●required to do prospective studies

POLL QUESTION

●not enough to enable AI systems to

generate new insights

● A greater diversity of data is needed.

● Providers use different EHR systems

● harder to link data sets

● Solving this is crucial

●not perfect

● data must be properly obtained

● hype is a continued threat

● need for sound science and

prospective studies.

● meaningful partnerships

● long-term vision

rapid increase in AI use

reason for optimism

vigilance will be necessary

clearer picture of winners and losers

top related